- LAVA Therapeutics N.V. (NASDAQ:LVTX) hosted a clinical update call focused on initial Phase 1/2a data for LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the American Society of Clinical Oncology and European Hematology Association meetings.
- "Although preliminary, these data support our view of LAVA-051 as a promising candidate that has the potential to overcome challenges of existing T-cell approaches, which frequently show cytokine release syndrome very close to their efficacious dose," said Arnon Kater, LAVA-051 clinical trial investigator.
- Related: LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial.
- The early clinical data from the first four cohorts demonstrate early signals of potential anti-tumor activity in CLL and MM patients and an attractive safety profile, Kater added.
- Notably, the pharmacodynamic determinations gathered from the patients in the early clinical study reflect the mechanism of action of LAVA-051, he added.
- LAVA-051 is a humanized Gammabody designed to activate both Vγ9Vδ2 (Vgamma9 Vdelta2) T cells and type 1 NKT cells to kill CD1d-expressing tumor cells.
- Price Action: LVTX shares closed at $2.78 on Thursday.
